

Prior Authorization Request Form for tazemetostat (Tazverik)



JOHNS HOPKINS
MEDICINE

JOHNS HOPKINS
HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

USFHP Pharmacy Prior Authorization Form

| To be completed by Requesting provider | |
|--|----------------------|
| Drug Name: | Strength: |
| Dosage/Frequency (SIG): | Duration of Therapy: |

**FAX Completed Form and
Applicable Progress Notes to:
(410) 424-4037**

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step 1 Please complete patient and physician information (please print):

| | |
|----------------------|-----------------------|
| Patient Name: _____ | Physician Name: _____ |
| Address: _____ | Address: _____ |
| Sponsor ID # _____ | Phone #: _____ |
| Date of Birth: _____ | Secure Fax #: _____ |

Step 2 Please complete the clinical assessment:

| | | |
|---|--|---|
| 1. Is the patient GREATER THAN or EQUAL to 16 years of age? | <input type="checkbox"/> Yes Proceed to question 2 | <input type="checkbox"/> No STOP Coverage not approved |
| 2. Is the requested medication prescribed by or in consultation with a hematologist/oncologist? | <input type="checkbox"/> Yes Proceed to question 3 | <input type="checkbox"/> No STOP Coverage not approved |
| 3. Does the patient have pathologically confirmed metastatic or locally advanced epithelioid sarcoma not eligible for complete resection? | <input type="checkbox"/> Yes Proceed to question 6 | <input type="checkbox"/> No Proceed to question 4 |
| 4. Please provide the indication or diagnosis. | <hr style="border: 0; border-top: 1px solid black;"/> Proceed to question 5 | |
| 5. Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation? | <input type="checkbox"/> Yes Proceed to question 6 | <input type="checkbox"/> No STOP Coverage not approved |
| 6. Will the patient be monitored for secondary malignancies (especially T-cell lymphoblastic lymphoma, myelodysplastic syndrome, and acute myeloid leukemia)? | <input type="checkbox"/> Yes Proceed to question 7 | <input type="checkbox"/> No STOP Coverage not approved |
| 7. What is the patient's gender? | <input type="checkbox"/> Male – Proceed to question 8 <input type="checkbox"/> Female – Proceed to question 9 | |

Prior Authorization Request Form for tazemetostat (Tazverik)

| | | |
|--|--|---|
| 8. Will the patient use effective contraception during treatment and for at least 3 months after the cessation of therapy? | <input type="checkbox"/> Yes Sign and date below | <input type="checkbox"/> No STOP Cov erage not approved |
| 9. Is the patient of childbearing potential? | <input type="checkbox"/> Yes Proceed to question 10 | <input type="checkbox"/> No Sign and date below |
| 10. Will the patient use effective contraception during treatment and for at least 6 months after the cessation of therapy? | <input type="checkbox"/> Yes Proceed to question 11 | <input type="checkbox"/> No STOP Cov erage not approved |
| 11. Is the patient pregnant? | <input type="checkbox"/> Yes STOP Cov erage not approved | <input type="checkbox"/> No Proceed to question 12 |
| 12. Has it been confirmed that the patient is not pregnant by (-) HCG? | <input type="checkbox"/> Yes Proceed to question 13 | <input type="checkbox"/> No STOP Cov erage not approved |
| 13. Will the patient breastfeed during treatment and for at least 1 week after the cessation of treatment? | <input type="checkbox"/> Yes STOP Cov erage not approved | <input type="checkbox"/> No Sign and date below |

Step 3 I certify the above is true to the best of my knowledge.
Please sign and date:

_____ Prescriber Signature

_____ Date

[05 August 2020]

| For Internal Use Only | |
|--|--------------------------------------|
| <input type="checkbox"/> Approved: | Duration of Approval: _____ month(s) |
| <input type="checkbox"/> Denied: | Authorized By: |
| <input type="checkbox"/> Incomplete/Other: | PA#: |
| Date Faxed to MD: | Date Decision Rendered: |